![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » MERGER SHOULD ADD VALUE TO BD CANCER SCREENING CAPABILITIES, ANALYST SAYS
MERGER SHOULD ADD VALUE TO BD CANCER SCREENING CAPABILITIES, ANALYST SAYS
Becton Dickinson's (BD) Dec. 20 acquisition of TriPath Imaging looks like a boon for BD, an analyst says.
BD acquired 93.5 percent of outstanding TriPath shares for $9.25 per share, a deal reportedly worth around $350 million.
"The TriPath acquisition fits nicely with BD's strategy to drive incremental revenue via entry into high-growth markets," Merrill Lynch Research analyst Lee Brown said in a Dec. 19 research note.
"TriPath provides BD with an attractive core business in cervical cancer screening, in which BD can add value," Brown said. "TriPath also offers BD a pipeline of diagnostic cancer tests that represent significant market opportunities and should enhance the competitiveness of BD's flow cytometry franchise."
The acquisition should accelerate BD's sales growth from 6 to 8 percent in fiscal 2007, with 7 to 8 percent type growth projected thereafter, Brown said.
KEYWORDS FDAnews Device Daily Bulletin
Upcoming Events
-
18Jul
-
21Oct